Summary of Study ST000573

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000421. The data can be accessed directly via it's Project DOI: 10.21228/M8N316 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Download binned data  
Download mwTab file (text)   |  Download mwTab file(JSON)
Study IDST000573
Study TitleExploratory research on first and second trimester urinary metabolic profiles and fetal growth restriction
Study SummaryFrom 2010 to 2012, women were recruited into The Infant Development and the Environment Study (TIDES) from obstetrical clinics affiliated with academic medical centers in four U.S. cities. Using previously collected first and second trimester urine samples from this prospective cohort of nearly 800 pregnancies, we designed a nested case control study aimed to determine whether maternal metabolic abnormalities/differences are associated with FGR. To find the patients with fetal growth restriction (FGR), we reviewed de-identified questionnaires and de-identified previously collected data, and performed a growth potential formula considering gestational age, infant gender, maternal and paternal height, and interaction of gestational age with maternal weight. Using a case:control ratio of 1:2, matched on study site, maternal age (± 2 years), parity, and infant's sex, 53 cases were matched to 106 controls for a total of 159 patients, and 318 samples (one in each ttrimester). The samples were analyses by NMR spectroscopy, using Bruker IVDr platform. Identification of FGR cases and controls: FGR cases were determined using the AUDIPOG formula for the average predicted birthweight for an infant with specific characteristics of: maternal height, age, and prenatal weight, as well as infant sex, gestational age, and birth rank. AUDIPOG formula: avg_pred_bw = 10,228066774 - 0,646727171*GA + 0,0259713417*GA² - 0,000291122*GA³ - 0,045467351*sex + 0,0606013862*rank - 0,013592585*rank² + 0,0009109473*rank³ + 0,0003976103*MA + 0,0019992269*MH + 0,0169049061*MW - 0,000171266*MW² + 5,8340462E-7*MW³ The natural logarithm of this average predicted birthweight was used with the observed birthweight to determine a z-score and percentile for each infant. If an infant fell into the 10th percentile for his or her given characteristics, then they were considered as having FGR. Otherwise they were considered in the pool of controls.
Institute
Mayo Clinic
Last NameVuckovic
First NameIvan
Address200 First St. SW, Rochester, Minnesota, 55905, USA
Emailvuckovic.ivan@mayo.edu
Phone507-288-0486
Submit Date2017-03-17
Analysis Type DetailNMR
Release Date2018-04-10
Release Version1
Ivan Vuckovic Ivan Vuckovic
https://dx.doi.org/10.21228/M8N316
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR000421
Project DOI:doi: 10.21228/M8N316
Project Title:Exploratory research on first and second trimester urinary metabolic profiles and fetal growth restriction
Project Summary:From 2010 to 2012, women were recruited into The Infant Development and the Environment Study (TIDES) from obstetrical clinics affiliated with academic medical centers in four U.S. cities. Using previously collected first and second trimester urine samples from this prospective cohort of nearly 800 pregnancies, we designed a nested case control study aimed to determine whether maternal metabolic abnormalities/differences are associated with FGR. To find the patients with fetal growth restriction (FGR), we reviewed de-identified questionnaires and de-identified previously collected data, and performed a growth potential formula considering gestational age, infant gender, maternal and paternal height, and interaction of gestational age with maternal weight. Using a case:control ratio of 1:2, matched on study site, maternal age (± 2 years), parity, and infant's sex, 53 cases were matched to 106 controls for a total of 159 patients, and 318 samples (one in each ttrimester). The samples were analyses by NMR spectroscopy, using Bruker IVDr platform.
Institute:Mayo Clinic
Last Name:Vuckovic
First Name:Ivan
Address:200 First St. SW, Rochester, Minnesota, 55905, USA
Email:vuckovic.ivan@mayo.edu
Phone:507-288-0486

Subject:

Subject ID:SU000595
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Species Group:Human

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Cases/Controls Trimester
SA0299871_19Case 1
SA0299882_133Case 1
SA0299891_15Case 1
SA0299901_20Case 1
SA0299912_127Case 1
SA0299922_126Case 1
SA0299933_231Case 1
SA0299941_78Case 1
SA0299952_128Case 1
SA0299961_11Case 1
SA0299972_174Case 1
SA0299985_304Case 1
SA0299995_303Case 1
SA0300005_307Case 1
SA0300015_309Case 1
SA0300021_31Case 1
SA0300032_182Case 1
SA0300042_179Case 1
SA0300051_12Case 1
SA0300062_118Case 1
SA0300071_51Case 1
SA0300081_67Case 1
SA0300091_69Case 1
SA0300101_54Case 1
SA0300111_52Case 1
SA0300121_64Case 1
SA0300131_57Case 1
SA0300141_70Case 1
SA0300151_73Case 1
SA0300161_47Case 1
SA0300171_37Case 1
SA0300181_36Case 1
SA0300192_184Case 1
SA0300201_38Case 1
SA0300212_121Case 1
SA0300222_113Case 1
SA0300232_114Case 1
SA0300241_42Case 1
SA0300251_34Case 1
SA0300261_16Case 1
SA0300273_196Case 1
SA0300283_241Case 1
SA0300293_263Case 1
SA0300303_265Case 1
SA0300315_287Case 1
SA0300323_189Case 1
SA0300333_269Case 1
SA0300343_185Case 1
SA0300353_250Case 1
SA0300363_187Case 1
SA0300375_282Case 1
SA0300383_248Case 1
SA0300395_284Case 1
SA0300403_258Case 2
SA0300411_86Case 2
SA0300421_85Case 2
SA0300432_168Case 2
SA0300441_79Case 2
SA0300452_171Case 2
SA0300462_169Case 2
SA0300471_30Case 2
SA0300483_237Case 2
SA0300493_219Case 2
SA0300501_84Case 2
SA0300515_280Case 2
SA0300521_82Case 2
SA0300533_276Case 2
SA0300542_150Case 2
SA0300552_102Case 2
SA0300562_144Case 2
SA0300572_103Case 2
SA0300582_100Case 2
SA0300592_108Case 2
SA0300603_257Case 2
SA0300612_101Case 2
SA0300623_274Case 2
SA0300632_147Case 2
SA0300641_89Case 2
SA0300652_160Case 2
SA0300663_242Case 2
SA0300675_294Case 2
SA0300682_155Case 2
SA0300693_243Case 2
SA0300702_98Case 2
SA0300712_149Case 2
SA0300722_162Case 2
SA0300733_200Case 2
SA0300743_224Case 2
SA0300755_317Case 2
SA0300761_25Case 2
SA0300775_312Case 2
SA0300783_216Case 2
SA0300793_209Case 2
SA0300801_21Case 2
SA0300811_22Case 2
SA0300825_296Case 2
SA0300835_315Case 2
SA0300845_299Case 2
SA0300853_214Case 2
SA0300863_220Case 2
Showing page 1 of 4     Results:    1  2  3  4  Next     Showing results 1 to 100 of 322

Collection:

Collection ID:CO000589
Collection Summary:Previously collected first and second trimester urine samples from this prospective cohort of nearly 800 pregnancies
Sample Type:Urine

Treatment:

Treatment ID:TR000609
Treatment Summary:First and second trimester urine samples from this prospective cohort of nearly 800 pregnancies

Sample Preparation:

Sampleprep ID:SP000602
Sampleprep Summary:Urine samples were shipped on dry ice and stored at -80ºC at The Metabolomics Core Lab at Mayo Clinic in Rochester, MN, where their metabolic profiles were analyzed. The samples were prepared and NMR spectra were recorded according to Bruker IVDr (in vitro diagnostics) SOPs[19]. The samples were thawed on ice and mixed with Bruker VERBR urine buffer (phosphate buffer pH 7.4 containing 0.1% TSP-d4) in 9:1 (v/v) ratio. Typically, a 550µl urine aliquot was transferred to an Eppendorf tube, then 61.1 µl of buffer was added and the mixture was vortexed for 20 seconds. The sample was spun down at 5000rpm and 600µl of supernatant was transferred to 5 mm NMR tubes. Pool samples have been prepared by combining aliquots of all samples. In our case we took 50ul of each sample, combined them and prepared 5 replicates.

Analysis:

Analysis ID:AN000883
Analysis Type:NMR
Num Factors:5

NMR:

NMR ID:NM000099
Analysis ID:AN000883
Instrument Name:Bruker 600 MHz Avance III HD spectrometer
Instrument Type:FT-NMR
NMR Experiment Type:1D 1H
Spectrometer Frequency:600 MHz
  logo